BioSpace News Archive

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today provided an update on its New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

DICE Therapeutics, Inc. announced that management will present at the following investor conferences.

Capricor Therapeutics will release its financial results for the third quarter ended September 30, 2022, after the market close on Thursday, November 10, 2022.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the third quarter of 2022 and summarized recent business highlights.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for third quarter 2022 and provided a business update.

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its third quarter ended September 30, 2022.

Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, reported third quarter 2022 financial results.

Immunic, Inc. announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2022 and provided a business update.